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Abstract
Purpose The Hunter Syndrome-Functional Outcomes for
Clinical Understanding Scale (HS-FOCUS) Questionnaire
is a patient and parent-completed disease-specific instru-
ment used in Hunter syndrome (mucopolysaccharidosis II),
a rare paediatric progressive multi-systemic lysosomal
storage disease. The objective of this study was to shorten
the number of items of the Questionnaire to reduce
response burden while maintaining its content validity.
Methods Data collected in a clinical trial were used. An
iterative process helped identifying redundant or low per-
forming items based on content validity and psychometric
properties. Validation on the retained items was assessed
using patients and parent’s responses in terms of reliability,
validity and responsiveness.
Results The HS-FOCUS was completed by 49 patients
and 84 parents. Items were mainly removed owing to high
floor effects, high inter-item correlations ([0.80) or inad-
equate content. The shortened patient and parent versions
(18 and 21 items) each contained five function domains.
Internal consistency and test–retest reliability were [0.70
for most domains, except Breathing and School/work.
Concurrent validity was demonstrated by significant cor-
relations ([0.30) with similar concepts of previously val-
idated measures. Significant differences were found in all
domain scores across levels of disability.
Conclusions The shortened HS-FOCUS is a reliable,
valid and responsive measure, where burden in answering
the Questionnaire was reduced without compromising its
validity.
Keywords Hunter syndrome  Mucopolysaccharidosis
type II  Lysosomal storage disease  Patient-reported
outcomes  Hunter Syndrome-Functional Outcomes for
Clinical Understanding Scale (HS-FOCUS)
Background
Hunter syndrome, mucopolysaccharidosis II (MPS II), is a
rare, X-linked, progressive, multi-systemic, lysosomal
storage disorder caused by a deficiency of the enzyme
iduronate-2-sulfatase [1] with an estimated incidence of 1
per 170,000 male births [2]. A wide spectrum of clinical
disease occurs from attenuated to severe, with highly var-
iable rates of progression and degree of organ involvement,
resulting in significant impairment of patient’s function and
quality of life [3].
In order to monitor disease progression and evaluate
treatment in clinical trials, a MPS II-specific instrument,
the Hunter Syndrome-Functional Outcomes for Clinical
Understanding Scale (HS-FOCUS) Questionnaire, was
developed by a group of experts led by Dr J Muenzer.
Parent-completed and patient self-reported Questionnaires
were created through the literature review and input from
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expert clinicians, parents and patients. Assessment of
measurement properties of the HS-FOCUS was recently
undertaken [4] and revealed that it was a valid and reliable
instrument but could be further improved by reducing
items that were redundant.
This communication is a follow-up to the previous
publication [4] with the objective to reduce the number of
items of the HS-FOCUS in order to have a shorter and
more efficient instrument that also decreases the respon-
dent burden.
Methods
Data collected in a Phase II/III trial (NCT00069641) [5] as
used in the validation study [4] were further analysed to
reduce the items and re-assess the measurement properties
of the shortened HS-FOCUS.
The original HS-FOCUS could be completed by parents/
caregivers (68 items) or patients themselves (54 items). In
both, items were grouped into six function domains:
Walking/standing, Reach/grip, Sleeping, School/work,
Activities and Breathing; and a satisfaction-with-function
and a botheredness-with-function domains [4]. The item
response scale ranged from 0 being ability to complete the
activity ‘without ANY difficulty’ to 4 as ‘UNABLE to do
so’. Average domain scores were computed using item
responses if less than half of them were missing or ‘not
applicable’.
Parents of patients of all ages responded to the parent-
completed HS-FOCUS and patients aged C12 years to the
self-reported version. The same participants also completed
the following measures:
• The Childhood Health Assessment Questionnaire
(CHAQ) A 30-item disease-specific instrument [6] that
comprises eight domains: dressing, arising, eating,
walking, reach, grip, hygiene and activities. Each
domain is scored from 0 ‘without ANY difficulty’ to
3 ‘UNABLE to do’, and the average of the domain
makes up the disability index score (DIS).
• Health Utilities Index (HUI3) A family of generic
health profiles and preference-based systems with eight
attributes: vision, hearing, speech, ambulation, dexter-
ity, emotion, cognition and pain, with five to six levels
per attribute [7]. It includes self-assessed and proxy-
assessed forms. The scoring system provides utility
(preference) scores on a scale where dead = 0 and
perfect health = 1.
• Childhood Health Questionnaire (CHQ) A generic
Questionnaire that measures 12 unique physical and
psychosocial concepts in the children’s version CHQ-
CF87 and 14 in the parent-completed CHQ-PF50:
physical functioning, role/social–emotional and role/
social–behavioural, role/social–physical, bodily pain,
general behaviour, mental health, self-esteem, general
health perceptions, change in health, parental impact–
emotional, parental impact–time, family activities and
family cohesion. Concept scores may also be combined
to derive overall physical and psychosocial scores [8]
from 0 to 100.
Statistical analysis of the parent-completed and patient
self-reported responses were analysed separately using
Stata/MP Ver.11.0 [9].
An iterative process was used to identify potentially
redundant or poorly performing items using distributional
characteristics of the HS-FOCUS item responses (mean,
standard deviation, % missing and % at floor and ceiling).
Each item identified was further reviewed and discussed
individually and in the domain context. Input from two
paediatric clinicians with long standing experience in
treating MPS II was sought throughout the process.
Potentially redundant items were identified by any of the
following criteria: high (C60 %) percentage of missing
responses suggesting the item was less relevant to MPS II
or it was not clear; floor effects with C60 % responding
‘without ANY difficulty’ suggesting the item had a low
impact on the majority of MPS II patients; high inter-item
correlations ([0.80) suggesting item was redundant; low
item-to-total scale correlation (\0.30) and poor clinical
relevance. Items were examined by clinical experts for fit
within the domain, who also ensured that no clinically
relevant items were deleted.
Measurement properties of the shortened HS-FOCUS
were then re-assessed. Internal consistency was assessed
using Cronbach’s alpha, with a[ 0.70 considered accept-
able [10–12]. Test–retest reliability was considered
acceptable when intra-class correlation coefficient (ICC)
[0.70 among stable subjects defined as those whose CHAQ
DIS score change did not exceed ±0.13 between baseline
and week 18 [13]. Concurrent validity was evaluated with
Spearman rank order correlations with CHAQ, CHQ and
HUI3 [13]; correlations C0.30 between these measures
were anticipated. Correlation with the original HS-FOCUS
[4] was also calculated to support that content validity was
maintained. Known-groups validity was determined using
analysis of variance (ANOVA) to compare the mean of the
shortened HS-FOCUS domain scores among three levels of
disability: mild (CHAQ DIS B0.63); mild-moderate
(CHAQ DIS [0.63 to B1.75) and moderate (CHAQ DIS
[1.75) [14]. The extent to which the shortened HS-
FOCUS could detect change in patients’ health status was
assessed by comparing the mean domain scores in patients
who showed improvement measured by a CHAQ DIS
decrease C0.13 [14] versus those who did not.
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Results
Altogether, 49 MPS II patients 12 years and older and 84
parents completed the HS-FOCUS. The average age when
diagnosed was 5 years (SD 4.75; median 4; P10–P90:
0–13). Patients’ demographic and clinical characteristics
have been previously described in the HS-FOCUS valida-
tion study [4].
Table 1 shows the number of items retained for each HS-
FOCUS domains and the reasons for item removal (the full
content of the items is not shown because HS-FOCUS is
proprietary). One of the items in the Sleeping domain was
moved to Breathing, and two items in the Activities domain
were moved to Grip/reach. Subsequently, the Sleeping
domain were removed from the HS-FOCUS because after
moving one item to breathing the remaining items were
considered inadequate, and also because there are other well-
established sleep measures (e.g., Tayside Children’s Sleep
Questionnaire [15] or the Infant Sleep Questionnaire (ISQ)
[16] ) that could be used to supplement the HS-FOCUS.
Consequently, both patient-completed (18 items) and
parent-completed (21 items) Questionnaires of the short-
ened HS-FOCUS each contained five functional domains
ranging from 0 to 3 (authors’ note: The HS-FOCUS is
currently not publicly available; plan for sharing is under
consideration, please contact Shire for more information).
Table 2 shows the correlation between the shortened ver-
sion and the original HS-FOCUS was above 0.85 except
for the parent version’s Activities score (r = 0.75), sup-
porting that content validity was maintained.
Except for the Breathing domain in the patient’s sample,
the internal consistency reliability for all five domains in the
shortened HS-FOCUS was very good, with a ranging from
0.67 to 0.90 and 0.76 to 0.87 in the patients and parents’
Table 1 Item reduction in the patient and parent versions of the HS-FOCUS
Domains Items retained in the patient
version
Items retained in the parent
version
Items retained Item removed (reasons for deletion)
Walking/
standing
4 out of 10 5 out of 10 Walk and stand
without getting
tired; able to step
on a stool or walk
up stairs
Walk flat feet; stand on one foot;
stand straight against a wall, etc.
(poor content validity; duplication
with other items and not cross-
culturally relevant)
Grip/reach 4 out of 12 (?2) 6 out of 12 (?2) Touch top of head;
put on shoes; button
a shirt; catch a
balls, turn book
pages, etc.
Pick up a hamburger with thumb and
fingers; clap hands together;
straight out arms to the side, etc.
(low correlation with other items in
the domain; high floor effects; poor
content validity)
Sleeping 0 out of 4 1 out of 5 that was moved to
the BREATHING domain
due to closeness in clinical
content




Fall asleep within 20 minutes; sleep
through night; feel rested after
sleep, etc. (inappropriate domain
for the clinical group)





Pay attention in school/work (poor
content validity)
Activities 5 out of 6: 3 in this domain; 2
more were moved to the
GRIP/REACH domain due
to closeness in clinical
content
4 out of 6: 2 in this domain;
plus 2 more were moved to
the GRIP/REACH domain




or play with others;
play video games
Go out with friends (poor content
validity)
Breathing 3 out of 6 3 out of 6 (?1) Breath without noise;
talk or do activities
without becoming
short of breath
Blow out a candle; breath easily





0 out of 6 Your child: 0 out of 6
You: 0 out of 6




0 out of 7 Your child: 0 out of 7
You: 0 out of 7
None Poor clinical relevance
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sample, respectively. Overall, complete data on the HS-
FOCUS and the CHAQ at baseline and week 18 was available
for 82 parents and 48 patients 12 years old and above, from
which 30 and 14 were rated stable, respectively. Good test–
retest reliability was found with ICC ranging from 0.72 to 0.97
using patient responses and from 0.64 to 0.90 with parent
responses. Concurrent validity indicated domains were con-
sistently correlated to other instruments in the expected way.
Moderate ([0.3) to high ([0.6) Spearman correlations were
found between all patient self-reported domains and most
CHAQ Scales; moderate to high correlations were found with
the CHQ physical function, role/social physical, bodily pain
and self-esteem scores, but low correlation (\0.3) with
behaviour-related items, general health perception, change in
health and family cohesion. Moderate to high correlations
were found with the HUI3 utility scores: hearing, ambulation,
dexterity, pain and overall HRQL utility. A similar correlation
structure was found for the parent-completed responses (data
not shown).
Excellent known-groups validity was shown with sta-
tistically significant differences (P \ 0.01) in the ANOVA
for most shortened HS-FOCUS domains between groups
(Table 3). Results also indicated ability to detect changes
in the patient’s condition with a statistically significant
difference (P \ 0.01) in score changes between the two
groups in all five domains (Table 4).
Table 2 Correlation coefficient between the original and shortened
HS-FOCUS domains scores at baseline










0.94 49 0.97 84
Grip/reach 0.94 49 0.91 84
School/work 0.94 44 0.87 79
Activities 0.88 48 0.75 84
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Conclusions
The shortened HS-FOCUS retains the items that assess the
most critical functions of patients with MPS II, and has
shown to be a reliable, valid and responsive tool. For rare
and debilitating diseases such as MPS II, good compliance
with any instrument used to monitor disease progression
over time and evaluate treatment benefits in clinical trials is
essential. At the same time, it is important to reduce the
respondent burden, especially in paediatric populations.
Respondent fatigue when completing the Questionnaire
may affect the validity of the scores [17]; therefore,
reducing the length of the Questionnaire is expected to
have a positive effect.
The current study is limited by the small sample size
overall and by unbalanced groups when assessing known
group validity; the latter may cause violation to the homo-
geneity of variance assumption of ANOVA. In addition, the
use of mean imputation has the risk of creating a biased score;
scoring should be further studied. Analyses were based on
data of the original HS-FOCUS, and the complete validation
of the shortened HS-FOCUS will be conducted in the future as
collection of more data is ongoing.
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